for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Horizon Pharma Plc confirms FY 2016 net sales, adj. EBITDA guidance

April 12 (Reuters) - Horizon Pharma Plc

* Confirming its full-year 2016 net sales guidance of $1.025 to $1.050 billion - SEC filing

* Confirming full-year 2016 adjusted EBITDA guidance of $505 to $520 million

* First-Quarter 2016 net sales guidance would represent 79 percent year-over-year growth at midpoint

* Second-Quarter 2016 net sales guidance would represent 35 percent year-over-year growth at midpoint.

* First-Quarter 2016 adjusted EBITDA guidance would represent 114 percent year-over-year growth at midpoint

* Second-Quarter 2016 adjusted EBITDA guidance would represent 45 percent year-over-year growth at midpoint Source text for Eikon: (1.usa.gov/1Q4tMK4 ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up